10月16日，海西新药暗盘涨超100%，总市值突破136亿港元！不计手续费，中签一手赚超4300港元；公司每股定价86.4港元，每手50股，将于10月17日正式挂牌交易。
海西新药是一家处于商业化阶段的制药公司，集研发、生产及销售能力于一体，具备在研创新药的管线，已商业化的产品组合主要包括用于消化系统疾病、心血管系统疾病、内分泌系统疾病、神经系统疾病及炎症疾病的仿制药，并建立拥有4款在研创新药的管线。
已就15款仿制药获得国家药监局批准，当中有四款入选国家带量采购（「VBP」）计划，包括：安必力®、海慧通®、瑞安妥®、赛西福®。
创新药管线专注于具有各种适应症的在研药物，包括一款创新在研肿瘤药物、一款潜在用于治疗湿性年龄相关性黄斑变性（wAMD，因视网膜下血管异常增生所致的视网膜疾病）/糖尿病性黄斑水肿（DME，因糖尿病导致液体渗入黄斑部）/视网膜静脉闭塞（RVO，因视网膜静脉阻塞导致视力丧失）的首款口服药物及另外两款处于临床前阶段，用于治疗肿瘤及呼吸系统疾病的创新在研药物。其中进度最快的是针对骨肉瘤的C019199，今年下半年开展III期试验。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
